4Chuthapicith S, Eremin JM, Sheemy M, et al. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer:chemoresistance of response to drug therapy [J]. Surgeon, 2006, 4(4): 211-9.
5Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: development and current status [J]. Int J Clin Oncol, 2006, 11 (3): 199-208.
6Tokunaga E,Oki E,Nishida K,et al.Trastuzumab and breast cancer:devdopmeat and current starus[J].Int J Clin Oncol,2006,11(3):199.
7Demonty G,Bernard-Marty C,Puglisi F,et al.Progress and newstandards of care in the management of HER-2 positive breast cancer[J].Eur J Cancer,2007,43:497-509.
8Razzak AR,Lin NU,Winer EP.Herterogeneity of breast cancer and im-plications of adjuvant chemotherapy.Breast cancer and implications ofadjuvant chemotherapy[J].Breast Cancer,2008,15:31-34.
9Eichler AF,Kuter I,Ryan P,et al.Survival in patients with brain me-tastases from breast cancer:the importance of HER-2 status[J].Canc-er,2008,112(11):2359-2367.
